Symposium on new aspects of antiarrhythmic therapy
Pharmacokinetics of antiarrhythmic drugs

https://doi.org/10.1016/0002-9149(78)90851-2Get rights and content

Abstract

A knowledge of the determinants of the plasma concentrations of antiarrhythmic drugs is important because variation in plasma levels is often greater than the desired therapeutic range. The basic principles of pharmacokinetics are outlined and their application to the design of dosage regimens descrlbed. These principles are Illustrated In a review of the pharmacokinetics of lidocaine and its congeners, procalnamide and its active metabolite (N-acetylprocainamide), quinidine, disopyramide, phenytoin and propranolol, with particular emphasis on the factors that contribute to altered disposition.

References (53)

  • J LeLoner et al.

    Pharmacokinetics of lidocaine after prolonged intravenous infusion in incomplicated myocardial infarction

    Ann Intern Med

    (1977)
  • ER Smith et al.

    The acute antiarrhythmic and toxic effects in mice and dogs of 2-ethylamino-2′6′-acetoxylidine (L-86), a metabolite of lidocaine

    J Pharmacol Exp Ther

    (1971)
  • J Blumer et al.

    The convulsant potency of lidocaine and its N-dealkylated metabolites

    J Pharmacol Exp Ther

    (1973)
  • RA Branch et al.

    The reduction of lidocaine clearance by dl-propranolol: an example of a hemo-dynamic drug interaction

    J Pharmacol Exp Ther

    (1973)
  • N Benoswitz et al.

    Lidocaine disposition in monkey and man. II. Effects of hemorrhage and sympathomimetic drug administration

    Clin Pharmacol Ther

    (1974)
  • CA Difazio et al.

    Lidocaine metabolism in normal and phenobarbital-pretreated dogs

    Anesthesiology

    (1972)
  • RA Branch et al.

    Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey

    J Pharmacol Exp Ther

    (1973)
  • DE Jewitt et al.

    Lidocaine in the management of arrhythmias after myocardial infarction

    Lancet

    (1968)
  • TO Cheng et al.

    Sinus standstill following intravenous lidocaine administration

    JAMA

    (1973)
  • DG McDevitt et al.

    Antiarrhythmic effects of a lidocaine congener, tocainide 2-amino-2′, 6′-propionoxylidide, in man

    Clin Pharmacol Ther

    (1976)
  • RA Winkle et al.

    Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide

    Circulation

    (1976)
  • D Lalka et al.

    Kinetics of the oral antiarrhythmic lidocaine congener, Tocainide

    Clin Pharmacol Ther

    (1976)
  • J Koch-Weser

    Pharmacokinetics of procainamide in man

    Ann NY Acad Sci

    (1971)
  • EV Glardina et al.

    Interminent intravenous procainamide to treat ventricular arrhythmias

    Ann Intern Med

    (1973)
  • J Koch-Weser et al.

    Procainamide dosage schedules, plasma concentrations, and clinical effects

    JAMA

    (1971)
  • WK Lee et al.

    Antiarrhythmic efficacy of N-aceiylprocainamide in patients with premature ventricular contractions

    Clin Pharmacol Ther

    (1976)
  • Cited by (28)

    • The inhibitory effects of nor-oleanane triterpenoid saponins from Stauntonia brachyanthera towards UDP-glucuronosyltransferases

      2016, Fitoterapia
      Citation Excerpt :

      Whereas, it must be pointed out that the data obtained in vitro sometimes tend to underestimate the inhibition of drug glucuronidation in vivo, and the pharmacokinetic parameters used here to calculate concentrations are mean values of the parameters reported, but interindividual variability is large. Quinidine, for example, could competitively influence the AZT glucuronidation by inhibiting UGT2B7, with Ki value of 186 μM [28], the actual therapeutic plasma concentration range in vivo was 2–5 μg/mL, equivalent to 6–15 μM [29]. That is to say, the actual effects of the compounds might be more potent than these calculated here.

    View all citing articles on Scopus

    This work is supported in part by National Institutes of Health Grants 15431 and 20770, Bethesda, Maryland.

    View full text